Enanta Pharmaceuticals, Inc.

General ticker "ENTA" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $211.6M (TTM average)

Enanta Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -8.3%.

Estimated limits based on current volatility of 5.4%: low 4.92$, high 5.48$

Factors to consider:

  • Current price 25.2% below estimated low
  • Earnings for 3 months up through Q1 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-09-30 to 2026-09-30

  • 2024-09-30 to 2025-09-30 estimated range: [7.05$, 15.72$]
  • 2025-09-30 to 2026-09-30 estimated range: [7.65$, 16.35$]

Financial Metrics affecting the ENTA estimates:

  • Negative: Non-GAAP EPS, $ of -5.48 <= 0.04
  • Negative: negative Operating income
  • Negative: Operating cash flow per share per price, % of -23.69 <= 1.79
  • Negative: negative Net income
  • Negative: Industry operating cash flow per share per price (median), % of -24.48 <= 2.82
  • Positive: 22.52 < Shareholder equity ratio, % of 34.20 <= 43.26
  • Positive: Interest expense per share, $ of 0.52 <= 0.67
  • Negative: Industry earnings per price (median), % of -32.02 <= 0
  • Positive: Inventory ratio change, % of 0 <= 0

Similar symbols

Short-term ENTA quotes

2025-03-282025-03-312025-04-012025-04-022025-04-032025-04-042025-04-072025-04-082025-04-092025-04-102025-04-112025-04-142025-04-152025-04-162025-04-172025-04-212025-04-222025-04-232025-04-242025-04-252025-04-282025-04-292025-04-302025-05-012025-05-022025-05-052025-05-062025-05-072025-05-082025-05-0944.555.56
Price $

Long-term ENTA plot with estimates

1020304050Jul 2023Jan 2024Jul 2024Jan 2025Jul 2025Jan 2026Jul 2026−1.5−1−0.50
ENTAS&P500Health CareNon-GAAP EPS EstimateNon-GAAP EPS ActualPrice $Non-GAAP EPS $

Financial data

YTD 2022-09-30 2023-09-30 2024-09-30
Operating Revenue $86.16MM $79.20MM $67.64MM
Operating Expenses $210.00MM $216.41MM $189.33MM
Operating Income $-123.84MM $-137.21MM $-121.69MM
Non-Operating Income $1.66MM $6.21MM $3.90MM
Interest Expense $0.00MM $5.15MM $10.94MM
R&D Expense $164.52MM $163.52MM $131.48MM
Income(Loss) $-122.19MM $-131.00MM $-117.79MM
Taxes $-0.43MM $2.82MM $-1.74MM
Profit(Loss)* $-121.75MM $-133.82MM $-116.05MM
Stockholders Equity $321.33MM $216.74MM $128.81MM
Assets $375.41MM $462.27MM $376.65MM
Operating Cash Flow $-84.78MM $-103.15MM $-78.76MM
Capital expenditure $2.12MM $9.06MM $17.95MM
Investing Cash Flow $54.90MM $-53.58MM $58.23MM
Financing Cash Flow $20.03MM $198.13MM $-27.63MM
Earnings Per Share** $-5.91 $-6.38 $-5.48

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.